ZC0109

ZC0109

Z658870-5mg

5mg

≥99%

-20°C储存

超低温冰袋运输

ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 ( TrxR1 ) with IC 50 s of 50 nM and 3.0 μM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads to cancer cells apoptosis. Appearance:Solid IC50& Target:IC50: 50 nM (IDO1), 3.0 μM (TrxR1) In Vitro:ZC0109 (24 h) inhibits cancer cells with IC 50 s of 3.44 μM (HCT-116), 12.4 μM (CT26), and 10.2 μM (HeLa), respectively. ZC0109 (2.5-10 μM; 24 h) induces ROS accumulation in HCT-116 and HeLa cells. ZC0109 (2.5-10 μM; 24 h) induces apoptosis and In Vivo:ZC0109 (15, 30, and 60mg/kg; p.o.; once daily for 28 d) reduces Kyn/Trp metabolism in C57BL/6 mice. ZC0109 (60mg/kg; p.o.; once daily for 28 d) decreases tumor growth and increases accumulation and infiltration of T cells in CT-26 cells transplante Biological Activity:ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 ( TrxR1 ) with IC 50 s of 50 nM and 3.0 μM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads to cancer cells apoptosis.

C22H20BrFN8O4S

591.41 g/mol

O/N=C(C1=NON=C1NCCCC2=NN=C(S2)NC(CC3=CC=C(C=C3)O)=O)\\NC4=CC(Br)=C(C=C4)F

DMSO : 50 mg/mL (84.54 mM; ultrasonic and warming and heat to 60°C)